Intrinsic Value of S&P & Nasdaq Contact Us

Medical Properties Trust, Inc. MPT NYSE

NYSE • Financial Services • REIT - Industrial • US • USD

SharesGrow Score
39/100
2/7 Pass
SharesGrow Intrinsic Value
$95.69
+1810%
Analyst Price Target
$6.50
+29.7%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Medical Properties Trust, Inc. (MPT) has a negative trailing P/E of -10.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 49.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.65%, forward earnings yield 2.03%. PEG 1.00 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (75/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (1.00); analyst target implies upside (+29.7%).
  • Forward P/E 49.3 — analysts expect a return to profitability with estimated EPS of $0.10 for FY2026.
  • PEG Ratio 1.00 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -9.65% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 2.03% as earnings recover.
  • Analyst consensus target $6.50 (+29.7% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 39/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
39/100
SG Score
View full scorecard →
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
~
FUTURE
46/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
MOAT
72/100
→ Income
GROWTH
15/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — MPT

Valuation Multiples
P/E (TTM)-10.4
Forward P/E49.3
PEG Ratio1.00
Forward PEG1.00
P/B Ratio0.62
P/S Ratio14.54
EV/EBITDA23.0
Per Share Data
EPS (TTM)$-0.46
Forward EPS (Est.)$0.10
Book Value / Share$7.67
Revenue / Share$1.62
FCF / Share$0.38
Yields & Fair Value
Earnings Yield-9.65%
Forward Earnings Yield2.03%
Dividend Yield7.11%
SharesGrow IV$95.69 (+1810%)
Analyst Target$6.50 (+29.7%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 14.2 0.41 0.99 5.92 6.82%
2017 16.6 -3.58 1.26 6.84 6.78%
2018 5.8 0.02 1.29 7.49 6.19%
2019 24.1 -0.35 1.28 10.36 4.57%
2020 26.7 -3.88 1.57 9.23 4.93%
2021 21.2 0.57 1.65 9.01 4.62%
2022 7.4 0.21 0.78 4.32 10.47%
2023 -5.3 0.03 0.39 3.37 20.94%
2024 -1.0 0.00 0.49 2.38 13.54%
2025 -10.8 0.12 0.65 3.09 6.43%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $0.86 $541.14M $225.05M 41.6%
2017 $0.82 $704.75M $289.79M 41.1%
2018 $2.76 $784.52M $1.02B 129.6%
2019 $0.87 $870.25M $374.68M 43.1%
2020 $0.81 $1.25B $431.45M 34.5%
2021 $1.11 $1.54B $656.02M 42.5%
2022 $1.50 $1.54B $902.6M 58.5%
2023 $-0.93 $871.8M $-556.48M -63.8%
2024 $-4.02 $995.55M $-2.41B -242.1%
2025 $-0.46 $972.02M $-277.05M -28.5%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $0.10 $0.10 – $0.10 $1B $993.59M – $1.01B 3
2027 $0.15 $0.14 – $0.16 $1.07B $1.06B – $1.08B 2
2028 $0.00 $0.00 – $0.00 $1.08B $1.06B – $1.08B 1
2029 $0.00 $0.00 – $0.00 $1.11B $1.1B – $1.12B 0
2030 $0.00 $0.00 – $0.00 $1.14B $1.13B – $1.15B 0
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message